ESR1 and breast carcinoma: Preclinical models demonstrated enhanced activation of the PI3K pathway in long-term estrogen deprived (LTED) ER+ breast cancer cells and a negative feedback system by which PI3K inhibition increases ER activity, potentially explaining the effectiveness of combinatorial mTOR and ER inhibition[15].